New targeted drug plus chemo for large b-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial compares a new targeted medicine (JS203) combined with chemotherapy against a standard treatment (rituximab) with chemotherapy for people whose large B-cell lymphoma has returned or not responded. The goal is to see if the new combination works better and to offer a possible new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your lymphoma must have the CD20 protein on the cells (this is a standard test).
- You must have tried at least one previous treatment that did not work or the lymphoma came back.
- You should be in reasonably good health (able to do light activity, no significant weakness).
- You must not have been treated before with a type of immunotherapy called a CD20-CD3 bispecific antibody.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug called TQB2825 given alongside standard chemotherapy (R-CHOP or GemOx) for people with diffuse large B-cell lymphoma (DLBCL) or a related type called grade 3b follicular lymphoma. The goal is to see if adding this new drug is safe and works better than standard treatment alone.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
This trial tests different combinations of targeted drugs and chemotherapy for people newly diagnosed with a type of lymphoma called DLBCL. It aims to find which combination is more effective and safer.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
This study tests a new drug combined with standard chemotherapy and immune therapy for people with diffuse large B-cell lymphoma. The goal is to see if the combination is safe and helps shrink or control the cancer.
This trial tests whether adding an extra targeted drug (called X) to the standard chemo (Pola-R-CHP) can help people with aggressive B-cell lymphoma that didn't respond well after the first round. It aims to improve outcomes for those who need a stronger treatment approach.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.